Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies

Hendrik Fuchs1, Nicole Niesler2, Alexandra Trautner3

  • 1Institut für Laboratoriumsmedizin, Klinische Chemie und Pathobiochemie, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, 13353 Berlin, Germany. hendrik.fuchs@charite.de.

Biomedicines
|May 25, 2017
PubMed

Insights

Targeted toxins show promise for cancer therapy but struggle with cell entry. This review explores glycosylated triterpenoids as enhancers to improve toxin delivery and efficacy in preclinical models.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Oncology

Background:

  • Protein-based targeted toxins are crucial for tumor therapies.
  • Limited toxin entry into target cell cytosol reduces efficacy.
  • Endosomal entrapment and degradation hinder therapeutic success.

Purpose of the Study:

  • To review glycosylated triterpenoids as endosomal escape enhancers.
  • To discuss their structure, mechanism, and efficacy.
  • To explore challenges and future prospects in targeted toxin therapy.

Main Methods:

  • Literature review on glycosylated triterpenoids.
  • Analysis of their role in endosomal escape.
  • Evaluation of efficacy in cell culture and animal models.

Main Results:

  • Glycosylated triterpenoids enhance endosomal escape of toxins.
  • Demonstrated efficacy in preclinical cell culture and animal models.
  • Overcoming endosomal entrapment is key for therapeutic advancement.

Conclusions:

  • Glycosylated triterpenoids represent a promising strategy to improve targeted toxin therapy.
  • Further research is needed to address obstacles and optimize clinical application.
  • Enhanced endosomal escape is critical for the success of antibody-targeted protein toxins.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
63
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.0K
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
51